INNV-30. RESPONSE WITH COMBINED DABRAFENIB AND TRAMETINIB AFTER BRAF INHIBITOR FAILURE IN BRAF-MUTATED GLIOBLASTOMA: A CASE REPORT

Glioblastoma (GBM) carries a poor prognosis despite aggressive multimodality therapy. Oncogenic BRAF mutations are present in < 2% of GBM, along with other glioma types (ganglioglioma, pleomorphic xanthoastrocytoma). Although oral inhibitors of the oncogenic BRAFv600 kinase have demonstrated some...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Kushnirsky, Marina, De la Fuente, Macarena I, Feun, Lynn
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Innovations in Patient Care
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847586/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.571
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items